BIOLOGICAL THERAPY WITH BENRALIZUMAB IN SEVERE EOSINOPHILIC ASTHMA: ADVANTAGES AND UNANSWERED QUESTIONS

Abstract

Biologic therapy is a breakthrough in the treatment of eosinophilic asthma. Inhibition of the interleukin-5 signalling pathway, such as with benralizumab, effectively reduces eosinophilic inflammation and asthma exacerbations, helps to achieve better control of asthma symptoms or a lower maintenance dose of glucocorticoids. Biologic therapy also has a good safety profile.However, there are the unaswered questions: does depletion of eosinophils not reduce the antiviral effects of eosinophils? Is tumorogenesis not promoted? A number of studies have been conducted to discuss these topics. In eosinophilic asthma, eosinophils are different from those in healthy individuals, so depletion is not a reasonable reason to think about the potential harm to human health.